Vivid Bioinnovations, Pbc SBIR award

Department of Health and Human Services, through National Institutes of Health, awarded Vivid Bioinnovations, Pbc of San Francisco, CA $1,319,519 under the SBIR program, with work starting 2025-09-12 and running to 2028-08-31. It is one of 3 SBIR and STTR awards Vivid Bioinnovations, Pbc received in the last two years, $2,133,088 in all. Each figure links to the federal record.

The award

Want the whole picture on Vivid Bioinnovations, Pbc?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Vivid Bioinnovations, Pbc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Vivid Bioinnovations, Pbc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   3 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

What it is for

A novel cell sorting technology to enable investigation of rare cells in primary human tissues - abstract rare cells, such as pathogenic astrocytes, play an important role in tissue physiology and pathology, including ne

Funding actions on this award

Find-seq: A novel cell sorting technology to enable investigation of rare cells in primary human tissues - abstract rare cells, such as pathogenic astrocytes, play an important role in tissue physiology and pathology, including neurodegenerative and cns disorders. However, the investigation of these cells is often hindered by the lack of known surface markers to isolate them, which is necessary for in-depth profiling. Find-seq, a novel cell sorting technology developed by dr. Adam abate, a founder of fluid discovery, which enables rare cells or nuclei to be isolated based on DNA or RNA markers with single molecule sensitivity, even in cases where no known surface markers are available. Fluid discovery, is focused on commercializing find-seq for neurodegenerative disease research and broader single-cell genomics markets. This fast-track SBIR will support the translation of the technology from the lab to the company, its development into a first-generation commercial product, and its validation on an important neurodegenerative disease use-case. The successful completion of these aims is crucial for the commercialization of find-seq and for fluid discovery's ability to meet the growing demand for more effective and efficient rare cell sorting and sequencing technologies.

From the federal award record.

Other SBIR and STTR awards to Vivid Bioinnovations, Pbc

Where this comes from

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.

Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.

All SBIR and STTR awards